FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2129374599> ?p ?o ?g. }

• W2129374599 endingPage "1032" @default.
• W2129374599 startingPage "1027" @default.
• W2129374599 abstract "Chemotherapy based on platinum is the standard treatment for unresectable malignant pleural mesothelioma (MPM). Liposomal doxorubicin (LD) consists of pegylated phospholipid vesicles that encapsulate doxorubicin-enhancing liposome deposition in the tumour. We evaluated the toxicity profile and anti-tumour activity of cisplatin plus LD in untreated patients with MPM, as well as 99mTc-LD distribution in MPM lesions after chemotherapy administration. A total of 38 patients with non-resectable MPM received LD 40 mg m−2 and cisplatin 60 mg m−2 every 21 days. Gamma camera images of 99mTc-LD were acquired to evaluate LD accumulation in measurable tumour tissue. The study was registered in Clinical Trials (NCT00886028). In all, 72% of patients were stage III and 28% were stage IV. Eighty four percent and 16% have high and low risk acording EORTC respectively. The median time to progression was 4.6 months (95% confidence interval (95% CI: 3.4–5.9 months), and median overall survival (OS) was 19.6 months (15.2–37.2 months). Patients that responded to chemotherapy treatment had better survival than patients who did not. Functional physical scales, dysnea, cough, and chest/arm pain demonstrated improvement. The accumulation ratio of LD in tumour and soft tissues vs liver was 0.78±0.16 and 0.29±0.09, respectively. After 1 h of administration, LD uptake in tumour tissue was higher than in soft tissue (P< 0.001). The combination of LD and cisplatin results in an active therapeutic regimen for unresectable MPM, with an acceptable toxicity profile and improvement in quality of life. 99mTc-LD showed higher levels of tumour uptake as compared with surrounding tissues." @default.
• W2129374599 created "2016-06-24" @default.
• W2129374599 creator A5004330353 @default.
• W2129374599 creator A5015043326 @default.
• W2129374599 creator A5019781989 @default.
• W2129374599 creator A5022721204 @default.
• W2129374599 creator A5035063101 @default.
• W2129374599 creator A5048049123 @default.
• W2129374599 creator A5061725810 @default.
• W2129374599 creator A5073172361 @default.
• W2129374599 creator A5084542730 @default.
• W2129374599 creator A5088794873 @default.
• W2129374599 date "2012-02-21" @default.
• W2129374599 modified "2023-10-06" @default.
• W2129374599 title "First-line chemotherapy with liposomal doxorubicin plus cisplatin for patients with advanced malignant pleural mesothelioma: phase II trial" @default.
• W2129374599 cites W148347120 @default.
• W2129374599 cites W1595731719 @default.
• W2129374599 cites W1769308960 @default.
• W2129374599 cites W1825790533 @default.
• W2129374599 cites W1919807248 @default.
• W2129374599 cites W1970090792 @default.
• W2129374599 cites W1975298683 @default.
• W2129374599 cites W1976428603 @default.
• W2129374599 cites W1990104009 @default.
• W2129374599 cites W2001061243 @default.
• W2129374599 cites W2036637417 @default.
• W2129374599 cites W2042532479 @default.
• W2129374599 cites W2043913125 @default.
• W2129374599 cites W2046147369 @default.
• W2129374599 cites W2051829053 @default.
• W2129374599 cites W2054256117 @default.
• W2129374599 cites W2061250724 @default.
• W2129374599 cites W2067137680 @default.
• W2129374599 cites W2092173244 @default.
• W2129374599 cites W2097157431 @default.
• W2129374599 cites W2100576484 @default.
• W2129374599 cites W2102627969 @default.
• W2129374599 cites W2103004443 @default.
• W2129374599 cites W2105015900 @default.
• W2129374599 cites W2112345476 @default.
• W2129374599 cites W2115425935 @default.
• W2129374599 cites W2122284070 @default.
• W2129374599 cites W2129967236 @default.
• W2129374599 cites W2137953688 @default.
• W2129374599 cites W2171227985 @default.
• W2129374599 cites W4250098627 @default.
• W2129374599 cites W4375939011 @default.
• W2129374599 doi "https://doi.org/10.1038/bjc.2012.44" @default.
• W2129374599 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3304415" @default.
• W2129374599 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/22353806" @default.
• W2129374599 hasPublicationYear "2012" @default.
• W2129374599 type Work @default.
• W2129374599 sameAs 2129374599 @default.
• W2129374599 citedByCount "38" @default.
• W2129374599 countsByYear W21293745992012 @default.
• W2129374599 countsByYear W21293745992013 @default.
• W2129374599 countsByYear W21293745992014 @default.
• W2129374599 countsByYear W21293745992015 @default.
• W2129374599 countsByYear W21293745992016 @default.
• W2129374599 countsByYear W21293745992017 @default.
• W2129374599 countsByYear W21293745992018 @default.
• W2129374599 countsByYear W21293745992019 @default.
• W2129374599 countsByYear W21293745992020 @default.
• W2129374599 countsByYear W21293745992021 @default.
• W2129374599 countsByYear W21293745992022 @default.
• W2129374599 countsByYear W21293745992023 @default.
• W2129374599 crossrefType "journal-article" @default.
• W2129374599 hasAuthorship W2129374599A5004330353 @default.
• W2129374599 hasAuthorship W2129374599A5015043326 @default.
• W2129374599 hasAuthorship W2129374599A5019781989 @default.
• W2129374599 hasAuthorship W2129374599A5022721204 @default.
• W2129374599 hasAuthorship W2129374599A5035063101 @default.
• W2129374599 hasAuthorship W2129374599A5048049123 @default.
• W2129374599 hasAuthorship W2129374599A5061725810 @default.
• W2129374599 hasAuthorship W2129374599A5073172361 @default.
• W2129374599 hasAuthorship W2129374599A5084542730 @default.
• W2129374599 hasAuthorship W2129374599A5088794873 @default.
• W2129374599 hasBestOaLocation W21293745991 @default.
• W2129374599 hasConcept C126322002 @default.
• W2129374599 hasConcept C126894567 @default.
• W2129374599 hasConcept C141071460 @default.
• W2129374599 hasConcept C142724271 @default.
• W2129374599 hasConcept C2776694085 @default.
• W2129374599 hasConcept C2777407522 @default.
• W2129374599 hasConcept C2778119113 @default.
• W2129374599 hasConcept C2778239845 @default.
• W2129374599 hasConcept C2778336483 @default.
• W2129374599 hasConcept C2780258809 @default.
• W2129374599 hasConcept C2781303535 @default.
• W2129374599 hasConcept C2781413609 @default.
• W2129374599 hasConcept C29730261 @default.
• W2129374599 hasConcept C71924100 @default.
• W2129374599 hasConcept C90924648 @default.
• W2129374599 hasConceptScore W2129374599C126322002 @default.
• W2129374599 hasConceptScore W2129374599C126894567 @default.
• W2129374599 hasConceptScore W2129374599C141071460 @default.
• W2129374599 hasConceptScore W2129374599C142724271 @default.
• W2129374599 hasConceptScore W2129374599C2776694085 @default.

• next